Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Income from Continuing Operations: 2014-2025

Historic Income from Continuing Operations for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$62.8 million.

  • Ascendis Pharma A's Income from Continuing Operations rose 41.10% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.4 million, marking a year-over-year increase of 47.15%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
  • Per Ascendis Pharma A's latest filing, its Income from Continuing Operations stood at -$62.8 million for Q3 2025, which was down 78.17% from -$35.3 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Income from Continuing Operations peaked at -$35.3 million during Q2 2025, and registered a low of -$200.7 million during Q4 2022.
  • Its 3-year average for Income from Continuing Operations is -$101.0 million, with a median of -$106.7 million in 2024.
  • As far as peak fluctuations go, Ascendis Pharma A's Income from Continuing Operations tumbled by 85.96% in 2022, and later surged by 69.93% in 2025.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Income from Continuing Operations stood at -$121.3 million in 2021, then plummeted by 65.42% to -$200.7 million in 2022, then skyrocketed by 59.64% to -$81.0 million in 2023, then soared by 52.12% to -$38.8 million in 2024, then spiked by 41.10% to -$62.8 million in 2025.
  • Its last three reported values are -$62.8 million in Q3 2025, -$35.3 million for Q2 2025, and -$99.5 million during Q1 2025.